Bicyclic compounds

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:

• wherein:
• R1 is selected from the group consisting of
• R2 is selected from the group consisting of
• X1A, X1B and X1C are independently selected from the group consisting of hydrogen, halogen, an unsubstituted C1-5 alkyl and an unsubstituted C1-5 haloalkyl;
• Y1A is CH, C—CHF2, C—F, C—Cl, C—(NH2), C(NH(unsubstituted C1-5 alkyl)), C(N(unsubstituted C1-5 alkyl)2) or N;
• Y2A is CH, C-halogen, C—OCH3, C—(NH2), C(NH(unsubstituted C1-5 alkyl)), C(N(unsubstituted C1-5 alkyl)2) or N;
• Y3A is CH or N;
• Y4A is CH or N;
• Y1B is CH, C—CHF2, C—F, C—Cl, C—(NH2), C(NH(unsubstituted C1-5 alkyl)), C(N(unsubstituted C1-5 alkyl)2) or N;
• Y2B is CH, C-halogen, C—OCH3, C—(NH2), C(NH(unsubstituted C1-5 alkyl)), C(N(unsubstituted C1-5 alkyl)2) or N;
• Y3B is CH or N;
• Y4B is CH or N;
• Y1C, Y2C, Y3C and Y4C are each independently CH, C-(halogen) or N;
• Y1D is CH, C—CH3, C—OCH3, C-(halogen), C—CHF2, C—CF3 or N;
• Y2D is CH, C—CH3, C—OCH3, C-(halogen), C—CHF2, C—CF3 or N;
• Y3D is CH, C-(halogen) or N;
• Y1E, Y1F and Y1G are each independently CH, C-(halogen) or N;
• Y1H, Y2H, Y3H, Y4H, Y5H and Y6H are each independently CH, C-(halogen) or N;
• RA1 is hydrogen, an unsubstituted or a substituted C1-5 alkyl or an unsubstituted or a substituted monocyclic C3-6 cycloalkyl, wherein when the C1-5 alkyl and the monocyclic C3-6 cycloalkyl are substituted, the C1-5 alkyl and the C3-6 cycloalkyl are substituted with one or more groups selected from the group consisting of hydroxy, —NH2, an unsubstituted C1-5 alkoxy, an unsubstituted-NH (an unsubstituted C1-5 alkyl), —N(an unsubstituted C1-5 alkyl)2, —C(═O) NH2, —O—P(═O)(OH)2, an unsubstituted 5- or 6-membered monocyclic heterocyclyl and 5- or 6-membered monocyclic heterocyclyl substituted by one or more unsubstituted C1-4 alkyl groups;
• RA2 is —CH3 or —CD3;
• RA3 is —NH2, —NH (an unsubstituted or a substituted C1-5 alkyl), —N(an unsubstituted or a substituted C1-5 alkyl)2, —NH (an unsubstituted or a substituted C3-6 monocyclic cycloalkyl), an unsubstituted or a substituted 5-membered-monocyclic heteroaryl, an unsubstituted or a substituted 6-membered-monocyclic heteroaryl or an unsubstituted or a substituted 4 to 6-membered-monocyclic heterocyclyl;
• RA4 is an unsubstituted or a substituted C1-5 alkyl, an unsubstituted C1-5 haloalkyl or an unsubstituted or a substituted monocyclic C3-6 cycloalkyl, wherein when the C1-5 alkyl and the monocyclic C3-6 cycloalkyl are substituted, the C1-5 alkyl and the C3-6 cycloalkyl are substituted with one or more groups selected from the group consisting of hydroxy, —C(═O) OH and —C(═O) NH2;
• and
• RA5 is selected from the group consisting of hydrogen, halogen, —CN, —OH, —NH2, —C(═O) OH, —CH═CH2, an unsubstituted C1-5 alkyl, and an unsubstituted or a substituted monocyclic C3-6 cycloalkyl, wherein when the monocyclic C3-6 cycloalkyl is substituted, the C3-6 cycloalkyl is substituted with one or more hydroxy groups;
• and
• wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is not:
• or a pharmaceutically acceptable salt thereof.